SciClone Reaches Agreement to Settle FCPA Derivative Suit

The suit — a consolidation of four similar plaintiff’s actions — alleged the Foster City, Calif.-based drugmaker made material misstatements about its financial results based on allegedly illegal and improper sales and marketing activities of hepatitis drug Zadaxin in China.

This story is exclusively for members of the
JUST ANTI-CORRUPTION COMMUNITY
Log-in
E-mail Address or UserName: *
Password: *
Subscribe
Click here to subscribe to
Just Anti-Corruption


For information about pricing, click here.
Paul Hastings LLP
ANALYSIS: Inside Out: The SEC Awards $1 Million Plus to Yet Another Compliance Professional Turned Whistleblower more
Steptoe & Johnson LLP
ANALYSIS: Does SEC’s Enforcement Action Against BHP Billiton Take the FCPA’s Accounting Provisions Too Far? more
Foley & Lardner LLP
ANALYSIS: Making the FCPA "Reasonable"— Exceptions and Affirmative Defenses more
Akin Gump Strauss Hauer & Feld LLP
ANALYSIS: Loretta Lynch Sworn in as New Attorney General – What’s Next? more
Kobre & Kim LLP
ANALYSIS: A New Balancing Act: Comparing the DOJ and World Bank Compliance Guidelines more
Strasburger & Price, LLP
ANALYSIS: Absolute Immunity from Defamation When Cooperating with Government Investigations? Maybe ‒ Maybe ... more

President Barack Obama speaks at outgoing Attorney General Eric Holder's portrait unveiling ceremony.



Attorney General Eric Holder called for a lower bar to federal civil rights prosecutions in an exit interview with Politico's Mike Allen.

USDOJ: CRIMINAL DIVISION NEWS  
An error has occurred, which probably means the feed is down. Try again later.